ストックスクリーナーアプリを入手
3.42
6.04%
-0.22
アフターアワーズ：
3.40
-0.02
-0.58%
前日終値:
$3.64
開ける：
$3.66
24時間の取引高:
5.15M
Relative Volume:
0.87
時価総額：
$2.50B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-3.5258
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-5.52%
1か月 パフォーマンス:
+6.21%
6か月 パフォーマンス:
-22.27%
1年 パフォーマンス:
-26.92%
1日の値動き範囲:
$3.40
$3.75
1週間の範囲:
$3.35
$4.27
52週間の値動き範囲:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
3.42 | 2.50B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio cleared to bring alternative BCG treatment source amid Merck shortage - MSN
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer - Yahoo
FDA approves expanded access for ImmunityBio's bladder cancer drug By Investing.com - Investing.com South Africa
Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? - Yahoo Finance
Sector Update: Health Care Stocks Advance Late Afternoon - TradingView
Sector Update: Health Care -February 19, 2025 at 03:41 pm EST - Marketscreener.com
Why ImmunityBio (IBRX) Is Surging Today - Yahoo Finance UK
ImmunityBio stock gains as FDA clears Merck rival (IBRX:NASDAQ) - Seeking Alpha
FDA Authorizes Immunitybio To Provide Rbcg To Urologists -February 19, 2025 at 10:16 am EST - Marketscreener.com
Why ImmunityBio’s Stock is Gaining Attention - TipRanks
FDA Authorizes ImmunityBio To Provide Recombinant Bcg (Rbcg) To Urologists To Address Tice® Bcg Shortage - Marketscreener.com
ImmunityBio Gets FDA Authorization for Expanded Access to Recombinant BCG for Bladder Cancer Treatment - Marketscreener.com
FDA approves expanded access for ImmunityBio's bladder cancer drug - Investing.com
Critical BCG Shortage Solution: FDA Grants Access to New Treatment SourceWhat Urologists Should Know - StockTitan
FDA Allows Use of Recombinant BCG Through Expanded Access Program - Monthly Prescribing Reference
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins - Baystreet.ca
ImmunityBio (NASDAQ:IBRX) Trading 12.6% HigherStill a Buy? - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio's Application for Anktiva Approved for Review in UK -February 13, 2025 at 03:38 pm EST - Marketscreener.com
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio announces executive compensation updates By Investing.com - Investing.com Canada
ImmunityBio announces executive compensation updates - MSN
ImmunityBio Approves 2024 Executive Bonuses and New Incentives - TipRanks
Major Regulatory Win: ImmunityBio's Cancer Drug ANKTIVA Advances in UK After US Success - StockTitan
Why Immunitybio Inc. (IBRX) Soared on Thursday - MSN
Natural Killer Cell Therapies Clinical and Non-Clinical - openPR
ImmunityBio (NASDAQ:IBRX) Shares Down 6.8%Time to Sell? - MarketBeat
ImmunityBio board member John Brennan resigns - MSN
ImmunityBio board member John Brennan resigns By Investing.com - Investing.com South Africa
IBRX 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm’s Attorneys Before Aug. 29th Deadline in Securities Fraud Class Action - ACCESS Newswire
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 6.8%Should You Sell? - MarketBeat
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation - MSN
ImmunityBio (NASDAQ:IBRX) Shares Up 17.2%Time to Buy? - MarketBeat
ImmunityBio and BeiGene ink research collaboration - The Pharma Letter
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva - BioSpace
Here’s Why ImmunityBio, Inc. (IBRX) Will Double in 2025 - Insider Monkey
ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo - Yahoo Finance
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism - MSN
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene - MarketWatch
Why ImmunityBio Stock is Gaining Momentum - TipRanks
ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy - Marketscreener.com
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital - MarketBeat
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - BioSpace
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA - Business Wire
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):